1-3 of 3
Hendrik van Deventer
Close
Sort by
Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-138786
Published: 2020
Journal Articles

Phase II Study of High Dose Cytarabine Followed By Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Joshua F Zeidner, MD, Benjamin G. Vincent, MD, Anastasia Ivanova, PhD, Matthew Foster, Catherine C. Coombs, MD, Katarzyna Jamieson, MD, Hendrik Van Deventer, MD, Richard Scibilia, Laura Blanchard, Cassiopeia Frank, Sean Gallagher, Melissa Matson, AGPCNP-BC, Katherine Pepin, Lori Vaught, Nancy Vogler, Ivana Gojo, MD, Leo Luznik, MD, Jonathan S Serody, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1349.
https://doi.org/10.1182/blood.V130.Suppl_1.1349.1349
Published: 2017
Journal Articles

CC chemokine receptor 8 potentiates donor T reg survival and is critical for the prevention of murine graft-versus-host disease

James M. Coghill, Kenneth A. Fowler, Michelle L. West, LeShara M. Fulton, Hendrik van Deventer, Karen P. McKinnon, Benjamin G. Vincent, Kaifeng Lin, Angela Panoskaltsis-Mortari, Donald N. Cook, Bruce R. Blazar, Jonathan S. Serody
Journal: Blood
Blood (2013) 122 (5): 825–836.
https://doi.org/10.1182/blood-2012-06-435735
Published: 2013
Includes: Supplemental data